cystic fibrosis epidemiology forecast

DelveInsight’s ‘Cystic Fibrosis (CF)- Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Cystic Fibrosis, historical and forecasted epidemiology as well as the CF trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Cystic Fibrosis Disease Understanding

Cystic Fibrosis (CF) is a life-limiting autosomal recessive genetic disorder that causes severe damage to the lungs and the digestive system. The disease is caused by a genetic mutation in the CFTR gene. The CFTR protein is a chloride-conducting trans-membrane conductance regulator and is called cystic fibrosis transmembrane conductance regulator. The mutation is autosomal recessive, which implies that the gene is not on the sex chromosome, and the symptoms would manifest only when both the alleles are mutated for the gene. CFTR protein is an ion channel and belongs to the ABC transporter class. Its gene is found on chromosome 7 in the long arm.

According to the clinical spectrum of cystic fibrosis, the disease can be classified into two categories, namely, classic and non-classic CF.

Classic CF: The majority of patients suffer from classic CF with their organs getting affected to various degrees. Patients are diagnosed with classic CF if they have one or more phenotypic characteristics and a sweat chloride concentration of >60 mmol/L; this is usually accompanied by exocrine pancreatic insufficiency (PI) or pancreatic sufficiency (PS). The disease can have either a rapid progression of symptoms or little deterioration over time.

Non-Classic CF: This category is described by having at least one CF phenotype, which is accompanied by a normal (<30 mmol/L) or borderline (30–60mmol/L) sweat chloride. They also have either single or multi-organ involvement; this is accompanied by exocrine PS and milder lung disease.

Cystic Fibrosis Diagnosis

The research and development over the last few years have contributed to the understanding of phenotypic and genotypic information of CFTR and has contributed to getting a clearer picture of the disease. Various diagnostic tools used for CFTR are:

a) Sweat test

It is the most reliable and widely available diagnostic test for CF, which involves the measurement of chloride concentration in sweat. Diagnosis with a sweat test must be made for infants with a positive NBS test. The body produces isotonic sweat in the secretory coil, but in the sweat ducts, most of the chloride is reabsorbed via the CFTR channel. Therefore, the sweat of healthy people is hypotonic. However, in individuals with dysfunctional CFTR, reabsorption of chloride does not occur, resulting in high chloride content in the sweat of people with CF. Pilocarpine iontophoresis is used for sweat induction which is followed by sweat collection on a gauze, filter paper (both requiring about 75 mg of sweat), or micro duct coil (requiring 50 mL). A minimum sweat rate of 1 g/m2 body surface area/min is required so that the collection time typically takes around 30 min. The sweat test is versatile in the sense that it can be performed in 2 weeks old who is normally hydrated and not acutely ill to adult individuals. Patients with CF would have a sweat chloride concentration above 60 mmol/L.

Continued in the report…..

Cystic Fibrosis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Cystic Fibrosis (CF), Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis (CF), Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis (CF), Mutation-specific Diagnosed Prevalent Cases of Cystic Fibrosis (CF) in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2021 to 2034.

Cystic Fibrosis Detailed Epidemiology Segmentation

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Cystic Fibrosis (CF) in the 7MM were 65,519 in 2021.
• The highest total diagnosed prevalent cases of Cystic Fibrosis were accounted by the US in 2021 (32,100 cases), which are expected to show a rise in the future.
• Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of CF with 10,922 cases, followed by the France, which had a diagnosed prevalent cases of 7,418 in 2021. On the other hand, Spain had the lowest diagnosed prevalent cases (2,520 cases).
• Japan had 47 total diagnosed prevalent cases of Cystic Fibrosis in 2021, accounting for approximately 0.1% in the 7MM.

Scope of the Report

• The report covers the descriptive overview of Cystic Fibrosis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Cystic Fibrosis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights

• 10-year forecast of Cystic Fibrosis
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Cystic Fibrosis

Key Questions Answered

• What are the disease risk and burden of Cystic Fibrosis?
• What is the historical Cystic Fibrosis patient pool in the United States, the EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Cystic Fibrosis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cystic Fibrosis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Cystic Fibrosis during the forecast period (2025-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

The Cystic Fibrosis report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Cystic Fibrosis epidemiology forecast.
• The Cystic Fibrosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Cystic Fibrosis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by segmentation
• Factors driving growth in a specific patient population